Literature DB >> 12391360

Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide.

K Fassbender1, M Stroick, T Bertsch, A Ragoschke, S Kuehl, S Walter, J Walter, K Brechtel, F Muehlhauser, K Von Bergmann, D Lütjohann.   

Abstract

Cerebral cholesterol metabolism has been linked with production of amyloid peptide (Abeta) crucial in AD. The association between use of cholesterol-lowering drugs (statins) and AD disease is currently being intensely discussed. In this case-control study on elderly nondemented subjects, the authors provide the first evidence that statins in clinically relevant dosages indeed affect cerebral cholesterol metabolism. However, these changes were not associated with altered intrathecal secretion of Alzheimer Abeta.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12391360     DOI： 10.1212/wnl.59.8.1257

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  31 in total

1.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

2.  Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease.

Authors:  Timothy M Hughes; Lewis H Kuller; Oscar L Lopez; James T Becker; Rhobert W Evans; Kim Sutton-Tyrrell; Caterina Rosano
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

3.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

Authors:  I Masse; R Bordet; D Deplanque; A Al Khedr; F Richard; C Libersa; F Pasquier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

4.  Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease.

Authors:  Kina Höglund; Steinar Syversen; Piotr Lewczuk; Anders Wallin; Jens Wiltfang; Kaj Blennow
Journal:  Exp Brain Res       Date:  2005-06-04       Impact factor: 1.972

5.  Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.

Authors:  Alberto Serrano-Pozo; Gloria L Vega; Dieter Lütjohann; Joseph J Locascio; Marsha K Tennis; Amy Deng; Alireza Atri; Bradley T Hyman; Michael C Irizarry; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

Review 6.  The effects of cholesterol on learning and memory.

Authors:  Bernard G Schreurs
Journal:  Neurosci Biobehav Rev       Date:  2010-05-12       Impact factor: 8.989

7.  CYP46A1 and the APOEε4 Allele Polymorphisms Correlate with the Risk of Alzheimer's Disease.

Authors:  Ling Li; Fan Zeng; Yu-Hui Liu; Hui-Yun Li; Shu-Yang Dong; Ze-Yan Peng; Yan-Jiang Wang; Hua-Dong Zhou
Journal:  Mol Neurobiol       Date:  2018-03-07       Impact factor: 5.590

Review 8.  Statins and dementia.

Authors:  Lewis H Kuller
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

Review 9.  [Statins for treatment of CNS diseases. Status report from research and clinical practice].

Authors:  T Menge; H-C von Büdingen; S S Zamvil; H-P Hartung; B C Kieseier; O Stüve
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

Review 10.  Brain cholesterol metabolism, oxysterols, and dementia.

Authors:  Timothy M Hughes; Caterina Rosano; Rhobert W Evans; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.